Pfizer Inc (PFE) 30.10 $PFE
Most active New York Stock Exchange-traded stocks
AP - Mon Jul 28, 5:05PM CDT
NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at the close of trading:
Final Glance: Pharmaceuticals companies
AP - Mon Jul 28, 5:05PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
Is Pfizer Inc. (PFE) Poised to Beat Earnings Estimates? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 28, 4:20PM CDT
Pfizer Inc. (PFE) is scheduled to report second quarter 2014 results before the opening bell on Jul 29.
Business events scheduled for Tuesday
By The Associated Press - AP - Mon Jul 28, 1:10PM CDT
Major business and economic events scheduled for Tuesday:
Midday Glance: Pharmaceuticals companies
AP - Mon Jul 28, 12:32PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
Pfizer, Merck, Amgen Near Q2 Earnings Reports
at Investor's Business Daily - Mon Jul 28, 12:02PM CDT
Big pharma Pfizer (PFE) got a downgrade ahead of its Q2 earnings report scheduled for Tuesday, a day that will also feature reports from fellow big pharma Merck (MRK) as well as big biotech Amgen (AMGN). Analysts on average expect Pfizer earnings of...
Pfizer (PFE) Breaks Through Support at $30.06
Comtex SmarTrend(R) - Mon Jul 28, 10:13AM CDT
Pfizer (NYSE
FE) has opened bearishly below the pivot of $30.21 today and has reached the first level of support at $30.06. Investors may be interested in a cross of the next downside pivot targets of $29.94 and $29.67.
Early Glance: Pharmaceuticals companies
AP - Mon Jul 28, 9:33AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
Why Pfizer (PFE) Stock Is Lower Today
at The Street - Mon Jul 28, 9:10AM CDT
Shares of Pfizer (PFE) are down in early morning trade as the drugmaker is expected to report significantly lower second quarter revenue tomorrow.
Will This Analyst Downgrade Hurt Pfizer (PFE) Stock Today?
at The Street - Mon Jul 28, 8:21AM CDT
BMO Capital Markets downgraded Pfizer (PFE) to "market perform" and set a $31 price target.
Another Heavy Earnings Week on Tap, as Pfizer, UPS, 5 Others Set to Report
at The Street - Mon Jul 28, 8:01AM CDT
Here are some trading guidelines for stocks of seven companies that are scheduled to report their quarterly results during the next two days.
Is a Surprise Coming for Pfizer (PFE) This Earnings Season? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jul 28, 7:54AM CDT
Pfizer (PFE) looks poised to beat at earnings season. That is because Pfizer is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.
Downgrade Alert for Pfizer (PFE)
Comtex SmarTrend(R) - Mon Jul 28, 7:11AM CDT
Pfizer (NYSE FE) was downgraded from Outperform to Market Perform at BMO Capital today. The stock closed yesterday at $30.19 on volume of 14.5 million shares, below average daily volume of 22.7 million. Pfizer Inc. is a research-based, global pharmaceutical company that discovers, develops, manufactures, and markets medicines for humans and animals. The Company's products include prescription pharmaceuticals, non-prescription self-medications, and animal health products such as anti-infective medicines and vaccines.
Global Rheumatoid Arthritis Drugs Market 2014-2018
M2 - Mon Jul 28, 6:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tv2rn2/global_rheumatoid) has announced the addition of the "Global Rheumatoid Arthritis Drugs Market 2014-2018" report to their offering. RA is a chronic disease that leads to inflammation and pain in the human body's joints such as wrists, fingers, knees, feet, and ankles. In addition, it causes inflammation of the tissues that surround the joints and in other organs. The symptoms of RA begin slowly, usually just mild pain around the joints coupled with stiffness and fatigue, and in the later stages it causes inflammation of the joints. It can occur at any age, even in children, which is called juvenile arthritis. The disease is three times more common in women than in men. Genetic and environmental elements are known to contribute in the development of RA. The analysts forecast the Global Rheumatoid Arthritis Drugs market will grow at a CAGR of 4.09 percent over the period 2013-2018. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Competitive Assessment of Top Drugs 08. Five Forces Analysis 09. Market Segmentation by Category 10. Geographical Segmentation 11. Buying Criteria 12. Rate of Incidence and Prevalence 13. Pipeline Snapshot 14. Market Growth Drivers 15. Drivers and their Impact 16. Market Challenges 17. Impact of Drivers and Challenges 18. Market Trends 19. Trends and their Impact 20. Vendor Landscape 21. Key Vendor Analysis 22. Other Reports in this Series Companies Mentioned: - AbbVie Inc. - Amgen Inc. - Bristol-Myers Squibb Co. - F. Hoffmann-La Roche Ltd. - Janssen Pharmaceuticals Inc. - Pfizer Inc. - AB Science SA - Astellas Pharma Inc. - AstraZeneca plc - Biogen Idec Inc. - Boehringer Ingelheim GmbH - Celgene Corp. - Daiichi Sankyo Co. Ltd. - Eli Lilly & Co. - GE Healthcare Co. - Genmab A/S - GSK plc - Incyte Corp. - Merck & Co. Inc. - Mitsubishi Tanabe Pharma Corp. - Novartis AG - Novo Nordisk A/S - Rigel Pharmaceuticals Inc. - Sanofi - Takeda Pharmaceutical Co. Ltd. - UCB SA - Vertex Pharmaceuticals Inc. For more information visit http://www.researchandmarkets.com/research/tv...rheumatoid
3 Dividend Value Stocks to Boost Your Income
Dan Caplinger, The Motley Fool - Motley Fool - Sat Jul 26, 12:05PM CDT
Dividend stocks are more popular than ever, with investors looking for more income from their investments. But with many dividend stocks fetching high prices, how can you find good values in the dividend arena? In the following video, Dan...
Why Obama Has Attacked Cross-Border Mergers at This Particular Time
at The Street - Fri Jul 25, 4:39PM CDT
Obama is speaking out against corporate deserters, accusing companies of giving up their citizenship. His focus appears to be more on the election in the fall than on the economy.
Most active New York Stock Exchange-traded stocks
AP - Mon Jul 28, 5:05PM CDT
NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at the close of trading:
Final Glance: Pharmaceuticals companies
AP - Mon Jul 28, 5:05PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
Is Pfizer Inc. (PFE) Poised to Beat Earnings Estimates? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 28, 4:20PM CDT
Pfizer Inc. (PFE) is scheduled to report second quarter 2014 results before the opening bell on Jul 29.
Business events scheduled for Tuesday
By The Associated Press - AP - Mon Jul 28, 1:10PM CDT
Major business and economic events scheduled for Tuesday:
Midday Glance: Pharmaceuticals companies
AP - Mon Jul 28, 12:32PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
Pfizer, Merck, Amgen Near Q2 Earnings Reports
at Investor's Business Daily - Mon Jul 28, 12:02PM CDT
Big pharma Pfizer (PFE) got a downgrade ahead of its Q2 earnings report scheduled for Tuesday, a day that will also feature reports from fellow big pharma Merck (MRK) as well as big biotech Amgen (AMGN). Analysts on average expect Pfizer earnings of...
Pfizer (PFE) Breaks Through Support at $30.06
Comtex SmarTrend(R) - Mon Jul 28, 10:13AM CDT
Pfizer (NYSE
FE) has opened bearishly below the pivot of $30.21 today and has reached the first level of support at $30.06. Investors may be interested in a cross of the next downside pivot targets of $29.94 and $29.67. Early Glance: Pharmaceuticals companies
AP - Mon Jul 28, 9:33AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
Why Pfizer (PFE) Stock Is Lower Today
at The Street - Mon Jul 28, 9:10AM CDT
Shares of Pfizer (PFE) are down in early morning trade as the drugmaker is expected to report significantly lower second quarter revenue tomorrow.
Will This Analyst Downgrade Hurt Pfizer (PFE) Stock Today?
at The Street - Mon Jul 28, 8:21AM CDT
BMO Capital Markets downgraded Pfizer (PFE) to "market perform" and set a $31 price target.
Another Heavy Earnings Week on Tap, as Pfizer, UPS, 5 Others Set to Report
at The Street - Mon Jul 28, 8:01AM CDT
Here are some trading guidelines for stocks of seven companies that are scheduled to report their quarterly results during the next two days.
Is a Surprise Coming for Pfizer (PFE) This Earnings Season? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jul 28, 7:54AM CDT
Pfizer (PFE) looks poised to beat at earnings season. That is because Pfizer is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.
Downgrade Alert for Pfizer (PFE)
Comtex SmarTrend(R) - Mon Jul 28, 7:11AM CDT
Pfizer (NYSE
FE) was downgraded from Outperform to Market Perform at BMO Capital today. The stock closed yesterday at $30.19 on volume of 14.5 million shares, below average daily volume of 22.7 million. Pfizer Inc. is a research-based, global pharmaceutical company that discovers, develops, manufactures, and markets medicines for humans and animals. The Company's products include prescription pharmaceuticals, non-prescription self-medications, and animal health products such as anti-infective medicines and vaccines. Global Rheumatoid Arthritis Drugs Market 2014-2018
M2 - Mon Jul 28, 6:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tv2rn2/global_rheumatoid) has announced the addition of the "Global Rheumatoid Arthritis Drugs Market 2014-2018" report to their offering. RA is a chronic disease that leads to inflammation and pain in the human body's joints such as wrists, fingers, knees, feet, and ankles. In addition, it causes inflammation of the tissues that surround the joints and in other organs. The symptoms of RA begin slowly, usually just mild pain around the joints coupled with stiffness and fatigue, and in the later stages it causes inflammation of the joints. It can occur at any age, even in children, which is called juvenile arthritis. The disease is three times more common in women than in men. Genetic and environmental elements are known to contribute in the development of RA. The analysts forecast the Global Rheumatoid Arthritis Drugs market will grow at a CAGR of 4.09 percent over the period 2013-2018. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Competitive Assessment of Top Drugs 08. Five Forces Analysis 09. Market Segmentation by Category 10. Geographical Segmentation 11. Buying Criteria 12. Rate of Incidence and Prevalence 13. Pipeline Snapshot 14. Market Growth Drivers 15. Drivers and their Impact 16. Market Challenges 17. Impact of Drivers and Challenges 18. Market Trends 19. Trends and their Impact 20. Vendor Landscape 21. Key Vendor Analysis 22. Other Reports in this Series Companies Mentioned: - AbbVie Inc. - Amgen Inc. - Bristol-Myers Squibb Co. - F. Hoffmann-La Roche Ltd. - Janssen Pharmaceuticals Inc. - Pfizer Inc. - AB Science SA - Astellas Pharma Inc. - AstraZeneca plc - Biogen Idec Inc. - Boehringer Ingelheim GmbH - Celgene Corp. - Daiichi Sankyo Co. Ltd. - Eli Lilly & Co. - GE Healthcare Co. - Genmab A/S - GSK plc - Incyte Corp. - Merck & Co. Inc. - Mitsubishi Tanabe Pharma Corp. - Novartis AG - Novo Nordisk A/S - Rigel Pharmaceuticals Inc. - Sanofi - Takeda Pharmaceutical Co. Ltd. - UCB SA - Vertex Pharmaceuticals Inc. For more information visit http://www.researchandmarkets.com/research/tv...rheumatoid
3 Dividend Value Stocks to Boost Your Income
Dan Caplinger, The Motley Fool - Motley Fool - Sat Jul 26, 12:05PM CDT
Dividend stocks are more popular than ever, with investors looking for more income from their investments. But with many dividend stocks fetching high prices, how can you find good values in the dividend arena? In the following video, Dan...
Why Obama Has Attacked Cross-Border Mergers at This Particular Time
at The Street - Fri Jul 25, 4:39PM CDT
Obama is speaking out against corporate deserters, accusing companies of giving up their citizenship. His focus appears to be more on the election in the fall than on the economy.
